Embolism

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA approval · 2026-08-25
EMA Authorised: Svariya (previously Rivaroxaban Koanaa) (rivaroxaban) — Koanaa Healthcare GmbH
EMA authorised Svariya (rivaroxaban) for prevention and treatment uses related to thromboembolic conditions; managed by Koanaa Healthcare Gm…